Impact of Antihyperlipidemic Therapy on Dental Implant Survival: A 10-Year Retrospective Cohort Study
Oral · 09.05.2026 · 6 (3) · 54
DOI: 10.3390/oral6030054 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Oral, online erschienen am 09.05.2026. Verfasst von Antony Chidiac und 8 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antihyperlipidemic medications are widely prescribed for the management of dyslipidemia and prevention of cardiovascular disease and may also influence bone metabolism, formation, and repair. However, their impact on peri-implant bone remodeling and dental implant survival remains insufficiently investigated.
Objectives
The aim of this study was to evaluate the influence of antihyperlipidemic therapy on dental implant survival and failure rates over a ten-year period.
Methods
A retrospective cohort study included 552 patients receiving 1680 dental implants between 2012 and 2022. Patients were divided into a control group (512 patients; 1581 implants) and a study group receiving antihyperlipidemic monotherapy (40 patients; 99 implants). Clinical, radiographic, and demographic data were collected and analyzed, and implant failure was assessed according to the established clinical criteria of the International Congress of Oral Implantologists.
Results
Kaplan–Meier analysis demonstrated significantly better dental implant survival in patients receiving antihyperlipidemic therapy (log-rank p = 0.046). The failure rate was lower in the study group (1.01%) compared with the control group (5.12%). Cox regression analysis, adjusted for age, sex, implant diameter and length, insertion torque, and bone quality, showed that antihyperlipidemic therapy was associated with a markedly reduced risk of implant failure (HR = 0.16). Overall, the use of antihyperlipidemic medications was associated with a significantly lower risk of implant failure (p < 0.05), suggesting a beneficial effect on long-term dental implant survival.
Conclusions
The present findings indicate that antihyperlipidemic therapy may be associated with improved dental implant survival and enhanced osseointegration. These results should be interpreted as hypothesis-generating and necessitate confirmation in future prospective randomized controlled studies with expanded and more balanced cohorts.
Zitieren
APA
Chidiac, A., Akl, C., Sadaka, R. M., Mrad, S., Navarrete-Hernández, J. D. J., Bourgi, R., Islas-Granillo, H., Cuevas-Suárez, C. E., & Bassil, J. (2026). Impact of Antihyperlipidemic Therapy on Dental Implant Survival: A 10-Year Retrospective Cohort Study. Oral, 6(3), 54. https://doi.org/10.3390/oral6030054
Vancouver
Chidiac A, Akl C, Sadaka RM, Mrad S, Navarrete-Hernández JDJ, Bourgi R, et al. Impact of Antihyperlipidemic Therapy on Dental Implant Survival: A 10-Year Retrospective Cohort Study. Oral. 2026;6(3):54. doi:10.3390/oral6030054
BibTeX
@article{Chidiac2026,
author = {Chidiac, Antony and Akl, Christia and Sadaka, Richard M. and Mrad, Stephanie and Navarrete-Hernández, José de Jesús and Bourgi, Rim and Islas-Granillo, Horacio and Cuevas-Suárez, Carlos Enrique and Bassil, Joseph},
title = {Impact of Antihyperlipidemic Therapy on Dental Implant Survival: A 10-Year Retrospective Cohort Study},
journal = {Oral},
year = {2026},
volume = {6},
number = {3},
pages = {54},
doi = {10.3390/oral6030054}
}
EUVIMED